The Company’s most advanced compound in development is bexagliflozin, a highly specific SGLT2 inhibitor for the treatment of type 2 diabetes. Clinical studies have established that bexagliflozin significantly reduces blood glucose and glycated hemoglobin in subjects with diabetes. Treatment with bexagliflozin also induces weight loss and a reduction in systolic and diastolic blood pressure. In a large gender-balanced international trial of 96 week duration, subjects assigned to treatment with bexagliflozin as monotherapy experienced fewer urinary tract infections and slightly fewer genital mycotic infections than subjects assigned to placebo. A predisposition to genital and genitourinary infections is the major recognized liability of the SGLT2 inhibitors as a class.
For more about information about SGLT2 please see below: